Abstract
Ceftriaxone-induced hemolytic anemia is a rare and often fatal phenomenon. We report here the case of a 6-year-old female with sickle cell disease who survived a brisk and profound hemolytic reaction, resulting in hemoglobin of 0.4 g/dL, after ceftriaxone infusion. Ongoing hemolysis was abrogated with aggressive supportive care, but the patient suffered extensive neurologic sequelae as a result of the event. Serologic testing confirmed the presence of ceftriaxone antibodies.
MeSH terms
-
Anemia, Hemolytic / blood
-
Anemia, Hemolytic / chemically induced*
-
Anemia, Hemolytic / immunology
-
Anemia, Hemolytic / therapy
-
Anemia, Sickle Cell / blood
-
Anemia, Sickle Cell / drug therapy*
-
Anemia, Sickle Cell / immunology
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / adverse effects*
-
Anti-Bacterial Agents / immunology
-
Antibodies / blood
-
Antibodies / immunology
-
Brain Ischemia / blood
-
Brain Ischemia / chemically induced*
-
Brain Ischemia / immunology
-
Brain Ischemia / therapy
-
Ceftriaxone / administration & dosage
-
Ceftriaxone / adverse effects*
-
Ceftriaxone / immunology
-
Child
-
Female
-
Hemolysis / drug effects*
-
Humans
Substances
-
Anti-Bacterial Agents
-
Antibodies
-
Ceftriaxone